{"gene":"GRK5","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1993,"finding":"GRK5 phosphorylates rhodopsin in a light-dependent manner and is not activated by G-protein βγ subunits, unlike βARK, and does not contain a consensus sequence for isoprenylation, distinguishing it from other GRK family members.","method":"Baculovirus/Sf9 overexpression, in vitro kinase assay, sequence analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted kinase assay with purified protein; independently replicated in multiple early biochemical characterization papers (PMIDs 8120045, 8288567)","pmids":["7685906"],"is_preprint":false},{"year":1994,"finding":"Purified GRK5 phosphorylates β2-adrenergic receptor, m2 muscarinic receptor, and rhodopsin in an agonist/light-dependent manner; major autophosphorylation sites mapped to Ser484 and Thr485; GRK5 associates with membranes constitutively and does not translocate upon agonist stimulation.","method":"Sf9 purification, in vitro kinase assay, peptide phosphorylation, autophosphorylation site mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — purified protein in vitro assay with multiple substrates and site mapping; replicated across two independent papers (PMIDs 8120045, 8288567)","pmids":["8120045","8288567"],"is_preprint":false},{"year":1994,"finding":"Phospholipid-stimulated autophosphorylation of GRK5 at Ser484 and Thr485 (C-terminal region, aa 489–590 mediates phospholipid interaction) activates GRK5; a non-autophosphorylatable S484A/T485A mutant has ~15–20-fold reduced ability to phosphorylate β2AR and rhodopsin.","method":"In vitro kinase assay, mutagenesis (S484A/T485A), GST fusion-protein phospholipid binding, phosphoamino acid analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with defined mutants, mutagenesis, multiple orthogonal methods in one study","pmids":["8144599"],"is_preprint":false},{"year":1997,"finding":"PKC phosphorylates GRK5 at two major sites within the C-terminal 26 amino acids, stoichiometrically reducing its ability to phosphorylate rhodopsin (~5-fold increased Km, ~3-fold decreased Vmax) and decreasing its ability to bind rhodopsin-containing membranes, without altering direct phospholipid binding.","method":"In vitro PKC phosphorylation assay, intact-cell PMA treatment of COS-1 cells, kinetic analysis, membrane-binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetic analysis plus intact-cell confirmation; single lab but multiple orthogonal methods","pmids":["9013639"],"is_preprint":false},{"year":1998,"finding":"Actin binds and inhibits GRK5: monomeric actin binds with Kd ~0.6 μM and filamentous actin with Kd ~0.2 μM; mutation of 6 N-terminal amino acids eliminates actin-mediated inhibition. Calmodulin (which binds the GRK5 N-terminus) displaces GRK5 from actin, selectively permitting phosphorylation of soluble but not membrane-bound GPCR substrates.","method":"In vitro binding assay, in vitro kinase assay, N-terminal mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with binding constants measured and mutagenesis; single lab, multiple orthogonal methods","pmids":["9685424"],"is_preprint":false},{"year":2004,"finding":"A predicted amphipathic helix (aa 546–565) in the GRK5 C-terminus mediates plasma membrane localization; hydrophobic residues within this helix are necessary for PM targeting of GFP fusion constructs and for phospholipid-dependent autophosphorylation and phosphorylation of membrane-bound rhodopsin.","method":"GFP fusion live-cell imaging, mutagenesis of hydrophobic/basic residues, autophosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence validated by mutagenesis; single lab, multiple orthogonal methods","pmids":["14976207"],"is_preprint":false},{"year":2007,"finding":"GRK5 is constitutively associated with β2AR at the plasma membrane (demonstrated by high basal BRET2 between β2AR-Rluc and GRK5-GFP2 that is not diminished by agonist). Extensively washed plasma membranes retain GRK5 and support agonist-dependent GRK site phosphorylation (pS355/356) of β2AR, while GRK2 is depleted.","method":"BRET2 assay, cell-free membrane phosphorylation assay, immunodepletion of GRKs","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — BRET2 co-localization and cell-free assay; single lab, single study","pmids":["18034461"],"is_preprint":false},{"year":2008,"finding":"GRK5-Leu41 (Q41L polymorphism) uncouples isoproterenol-stimulated β-adrenergic responses more effectively than GRK5-Gln41 in transfected cells and transgenic mice, providing enhanced βAR desensitization ('genetic beta-blockade') and protecting against catecholamine-induced cardiomyopathy.","method":"Transfected cell functional assay, transgenic mouse model, catecholamine challenge model","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional assays in cells and in vivo transgenic model, multiple orthogonal approaches in one study, widely cited","pmids":["18425130"],"is_preprint":false},{"year":2009,"finding":"GRK5 phosphorylates β-arrestin1 at Ser412 when β-arrestin1 is bound to the phosphorylated 5-HT4 receptor C-terminus; this phosphorylated β-arrestin1 prevents activation of Src constitutively bound to the receptor, thereby inhibiting the G protein-independent Src/ERK signaling pathway.","method":"Co-immunoprecipitation, phosphorylation assay, site-directed mutagenesis, ERK activity measurement in HEK-293 cells and neurons","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphorylation site identified biochemically with mutagenesis and functional readout in two cell types; single lab, multiple orthogonal methods","pmids":["19661922"],"is_preprint":false},{"year":2011,"finding":"GRK5 promotes F-actin bundling and targets bundles to plasma membrane structures via simultaneous interaction with F-actin and phosphatidylinositol-4,5-bisphosphate; separate domains of GRK5 mediate actin cytoskeleton coupling and membrane remodeling, and this function (not kinase activity) is required for neurite outgrowth, dendrite branching, and spine morphogenesis. GRK5 KO mice display immature spine morphology and deficient learning and memory.","method":"Domain deletion/mutagenesis, in vitro F-actin bundling assay, live-cell imaging, GRK5 KO mouse behavioral and morphological analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro actin bundling reconstitution plus KO mouse phenotype with morphological readout; single lab, multiple orthogonal methods","pmids":["21930777"],"is_preprint":false},{"year":2002,"finding":"In hypertensive heart failure-prone (SHHF) rat cardiomyocytes, GRK5 specifically accumulates in the nucleus (colocalizing with coilin, a component of nuclear substructures involved in RNA synthesis/processing), whereas in normal WKY myocytes it distributes diffusely in the cytoplasm.","method":"Subcellular fractionation, fluorescent confocal microscopy, co-localization with nuclear markers","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct localization by fractionation and confocal microscopy; single lab, single study, no direct functional consequence tested","pmids":["12052842"],"is_preprint":false},{"year":2013,"finding":"GRK5 contains a nuclear localization sequence (NLS) that also binds DNA in vitro; the DNA-binding ability requires both the NLS and an N-terminal calmodulin-binding site. A functional nuclear export sequence (NES) was identified that mediates Ca2+/CaM-dependent nuclear export. GRK5 nuclear localization is differentially regulated from GRK4 and GRK6 subfamily members.","method":"GRK5/GRK4/GRK6 chimera analysis, mutagenesis, in vitro DNA-binding assay, live-cell nuclear localization imaging","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro DNA-binding plus cell localization with mutagenesis; single lab, two orthogonal methods","pmids":["23658733"],"is_preprint":false},{"year":2013,"finding":"Nuclear GRK5 increases NF-κB p50 and p65 levels, promotes p65 phosphorylation, increases NF-κB DNA binding activity, and drives NF-κB reporter activity in cardiomyocytes; a nuclear-localization-deficient GRK5 mutant loses these effects, indicating dependence on nuclear translocation.","method":"Adenoviral overexpression, siRNA knockdown in NRVMs, NF-κB reporter assay, EMSA, co-immunoprecipitation, nuclear-localization mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple readouts including NLS mutant; single lab, multiple orthogonal methods","pmids":["24174526"],"is_preprint":false},{"year":2014,"finding":"Nuclear GRK5 enhances NFAT-mediated hypertrophic gene transcription in cardiomyocytes via direct DNA binding (without a phosphorylation event); GRK5 transgenic mice show elevated NFAT reporter activity basally and after TAC/PE; GRK5 null mice have reduced NFAT activity after TAC; loss of NFATc3 protects GRK5-overexpressing mice from exaggerated hypertrophy.","method":"NFAT-luciferase reporter, transgenic and knockout mouse TAC model, adenoviral gene transfer, molecular DNA-binding studies, epistasis via NFATc3 KO","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple gain/loss-of-function models in cells and mice with epistasis; single lab, multiple orthogonal methods and replicated across experiments","pmids":["25332207"],"is_preprint":false},{"year":2014,"finding":"GRK5 phosphorylates moesin at Thr66 (identified by mass spectrometry and confirmed by mutation), regulates moesin subcellular distribution, colocalizes with moesin at the cell periphery, and controls prostate cancer cell migration, invasion, and focal adhesion formation.","method":"Mass spectrometric phosphoproteome, in vitro kinase assay, T66 mutagenesis, co-localization imaging, GRK5 siRNA knockdown, xenograft model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphorylation site identified by MS and confirmed by mutagenesis with functional cell assays and in vivo xenograft; single lab, multiple orthogonal methods","pmids":["24755472"],"is_preprint":false},{"year":2009,"finding":"GRK5 deficiency selectively impairs desensitization of presynaptic M2/M4 muscarinic autoreceptors (not M1 receptors), causing reduced internalization of M2/M4 upon agonist treatment, leading to reduced hippocampal acetylcholine release that is correctable by M2/M4 antagonist methoctramine or pertussis toxin.","method":"Dominant-negative GRK5 overexpression in cholinergic cells, GRK5 KO hippocampal slices, ACh release measurement, receptor immunoreactivity assay, pharmacological rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function in cell line and KO slices with defined pharmacological rescue; single lab, two orthogonal model systems","pmids":["19478075"],"is_preprint":false},{"year":2015,"finding":"GRK5 and GRK2 differentially phosphorylate neurotensin receptor 1 (NTSR1): GRK2 phosphorylates only C-terminal Ser residues in an agonist-dependent manner, while GRK5 phosphorylates Ser/Thr in intracellular loop 3 and C-terminus in an activation-independent manner; negatively charged lipids in the immediate vicinity of NTSR1 directly affect phosphorylation by GRKs.","method":"Nanodisc reconstitution in vitro phosphorylation, mass spectrometry phosphosite mapping, NTSR1 mutant panel","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with nanodisc technology plus MS site mapping and mutagenesis; single lab, rigorous biochemical approach","pmids":["26120872"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of full-length human GRK5 at 1.8 Å resolution reveals that the C-terminal tail (AST segment) forms novel interactions with the nucleotide and N-lobe not previously observed in other GRKs; the NLT is displaced from positions seen in other GRKs; autophosphorylation sites in the NLT can undergo rapid cis-autophosphorylation despite being >20 Å from the catalytic cleft.","method":"X-ray crystallography (1.8 Å), ATP-analog/sangivamycin co-crystals, structural comparison with AGC family members","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution crystal structure with functional structural analysis; single study but Tier 1 method","pmids":["26032409"],"is_preprint":false},{"year":2017,"finding":"GRK5 forms a dynamic complex with agonist-occupied β2AR involving large conformational changes at the RH/catalytic domain interface; contacts occur between β2AR intracellular loops 2 and 3 and C-terminus with GRK5 RH bundle subdomain, membrane-binding surface, and kinase catalytic cleft, respectively.","method":"Cross-linking mass spectrometry, hydrogen-deuterium exchange MS, electron microscopy, mutagenesis, molecular dynamics simulations, computational docking","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — comprehensive integrated structural/biochemical approach with multiple orthogonal methods (HDX-MS, XL-MS, EM, mutagenesis, MD) in one rigorous study","pmids":["28431242"],"is_preprint":false},{"year":2014,"finding":"The RGS domain of GRK5 contains a hydrophobic dimeric interface (HDI) region that mediates GRK5 self-association/dimerization and is critical for plasma membrane localization; disruption of dimerization (M165E/F166E) reduces PM localization and impairs PAR1-induced calcium release regulation, which is rescued by forced dimerization or by adding an extra membrane-binding region.","method":"GRK5/GRK4 chimeras, point mutagenesis, co-immunoprecipitation, acceptor photobleaching FRET, calcium release functional assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — coIP and FRET for dimerization, mutagenesis with functional readout; single lab, two orthogonal methods","pmids":["24807909"],"is_preprint":false},{"year":2019,"finding":"Ca2+·CaM binds primarily to the small lobe of the GRK5 kinase domain near elements critical for receptor interaction and membrane association, inhibiting receptor phosphorylation while activating the kinase for phosphorylation of soluble substrates; using the natural product malbrancheamide as a probe, the C-terminal lobe of CaM was shown to regulate membrane binding while the N-terminal lobe regulates receptor phosphorylation and kinase activation; in cells, malbrancheamide attenuates GRK5 nuclear translocation and blocks the hypertrophic response.","method":"Small-angle X-ray scattering, negative-stain EM, natural product chemical probe (malbrancheamide), in-cell nuclear translocation assay, hypertrophic gene expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — SAXS structural data plus chemical probe pharmacology and cell-based functional assay; single lab, multiple orthogonal methods","pmids":["31337679"],"is_preprint":false},{"year":2020,"finding":"Crystal/cryo structure of GRK5–calmodulin complex reveals that CaM N and C domains bind independently to two helical regions at GRK5 N and C termini: the C domain disrupts membrane association facilitating cytoplasmic translocation, while the N domain activates GRK5 via ordering of the amphipathic αN-helix and allosteric disruption of kinase-RH domain interaction, enabling phosphorylation of cytoplasmic substrates.","method":"Cryo-EM/crystal structure, molecular dynamics simulations, biochemical kinase assays, localization experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution structural data with computational and biochemical validation providing mechanistic model for CaM regulation of GRK5 localization and activity","pmids":["33321095"],"is_preprint":false},{"year":2020,"finding":"GRK5 phosphorylates and inhibits the cardiac mineralocorticoid receptor (MR) upon β2-adrenergic receptor activation in cardiomyocytes, suppressing aldosterone-induced MR transcriptional activity; GRK5 deletion augments MR transcriptional activity and GRK5 is necessary for protective effects of eplerenone against aldosterone-induced apoptosis.","method":"CRISPR/Cas9 GRK5 deletion in H9c2 cells, GRK5 overexpression, co-immunoprecipitation, MR luciferase reporter, adult rat ventricular myocytes","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus reporter assay and CRISPR KO with functional readout; single lab, two orthogonal approaches","pmids":["32326036"],"is_preprint":false},{"year":2020,"finding":"GRK5 is necessary to promote agonist-induced dissociation of SAP97 from β1AR; cardiac-specific deletion of GRK5 prevents adrenergic-induced dissociation of the β1AR-SAP97 complex and prevents increases in CaMKII activity in hearts.","method":"Cardiac-specific GRK5 conditional KO mice, co-immunoprecipitation of β1AR-SAP97 complex, CaMKII activity measurement after isoproterenol challenge","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with biochemical co-IP and kinase activity readout; single lab, two orthogonal methods","pmids":["32507058"],"is_preprint":false},{"year":2021,"finding":"Nuclear translocation of GRK5 is involved in cardiac fibroblast activation; fibroblast-specific GRK5 deletion inhibits angiotensin II-mediated fibroblast activation in vitro and reduces cardiac fibrosis and hypertrophy after chronic AngII infusion or ischemic injury in vivo.","method":"Adult cardiac fibroblast GRK5 KO, fibroblast-specific conditional KO mice, AngII infusion model, MI model, nuclear translocation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-specific KO with multiple in vivo disease models and mechanistic nuclear translocation assay; single lab, multiple orthogonal experiments","pmids":["33500351"],"is_preprint":false},{"year":2021,"finding":"A peptide encoding the GRK5 N-terminal (GRK5nt) CaM-binding domain acts as a competitive inhibitor by binding Ca2+-CaM and preventing its association with endogenous GRK5, thereby blocking GRK5 nuclear accumulation after pressure overload and attenuating pathological NFAT and NF-κB transcription and cardiac hypertrophy.","method":"Adenoviral GRK5nt expression in NRVMs, transgenic cardiomyocyte-specific TgGRK5nt mice, TAC model, CaM-binding co-immunoprecipitation, NFAT/NF-κB reporters","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mechanistic peptide inhibitor with defined target (CaM-GRK5 interaction), cell and in vivo confirmation; single lab, multiple orthogonal methods","pmids":["33785612"],"is_preprint":false},{"year":2022,"finding":"Heterotrimeric Gq acts as a determinant of GRK subtype selectivity: upon Ang II stimulation of AT1R, β-arrestin recruitment depends on both GRK2/3 and GRK5/6; with β-arrestin-biased ligand TRV027 or pharmacological/genetic loss of Gq, GRK selectivity shifts to solely GRK5/6. Single-molecule imaging shows that under Gq-inactive conditions, AT1R and GRK5 (but not GRK2) relocate to an immobile phase.","method":"GRK-selective pharmacological inhibition, GRK genetic knockout, β-arrestin recruitment assay (BRET/NanoBiT), single-molecule live-cell imaging","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pharmacological and genetic perturbations with single-molecule imaging readout; multiple orthogonal methods, rigorous controls","pmids":["35078997"],"is_preprint":false},{"year":2022,"finding":"Catalytic inactivation of GRK5 (K215R knock-in mice) causes marked decline in cardiac function with increased apoptosis and fibrosis at baseline; nuclear restriction of K215R GRK5 in cardiomyocytes enhances cell death with higher p53 levels; K215R mutation promotes fibroblast-to-myofibroblast transition.","method":"Knock-in mouse model (K215R catalytic-dead GRK5), echocardiography, histology, in vitro cardiomyocyte and fibroblast studies","journal":"JACC. Basic to translational science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic-dead knock-in mouse with cell biological mechanistic follow-up; single lab, two experimental systems","pmids":["35540100"],"is_preprint":false},{"year":2022,"finding":"GRK5 is essential for finerenone-induced GRK5-dependent MR phosphorylation and inverse agonism in cardiomyocytes; GRK5 genetic deletion renders finerenone incapable of blocking cardiac MR transcriptional activity, establishing GRK5 as a co-repressor of the cardiac mineralocorticoid receptor.","method":"GRK5 genetic deletion (H9c2 cells), MR luciferase reporter assay, MR phosphorylation assay, finerenone vs. eplerenone comparison","journal":"World journal of cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic deletion with reporter and phosphorylation assay; single lab, single study but two pharmacological comparators","pmids":["35582468"],"is_preprint":false},{"year":2018,"finding":"GRK5 regulates phosphorylation of HDAC5 in pancreatic β cells; β cell-specific Grk5 KO mice show impaired glucose tolerance with reduced β cell mass and upregulation of cell cycle inhibitor Cdkn1a, with reduced transcription of immediate-early genes (Nr4a1, Fosb, Junb, Arc, Egr1, Srf) downstream of HDAC5 phosphorylation.","method":"β cell-specific Grk5 KO mice, glucose tolerance test, β cell mass quantification, RNA sequencing, HDAC5 phosphorylation assay","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-specific KO with defined pathway (GRK5-HDAC5-IEG) and multiple molecular readouts; single lab","pmids":["37520700"],"is_preprint":false},{"year":2024,"finding":"GRK5 phosphorylates HDAC6 in chondrocytes, promoting HDAC6 phosphorylation; KLF9 transcriptionally drives GRK5 expression by directly targeting the GRK5 promoter; GRK5 knockdown eliminates KLF9 overexpression effects on chondrocyte ECM degradation and apoptosis in osteoarthritis.","method":"ChIP/luciferase for KLF9-GRK5 promoter binding, GRK5-HDAC6 co-immunoprecipitation, HDAC6 phosphorylation assay, siRNA knockdown, HDAC6 inhibitor rescue","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP showing upstream regulation plus biochemical co-IP and phosphorylation with functional rescue; single lab, multiple orthogonal methods","pmids":["39779910"],"is_preprint":false},{"year":2024,"finding":"GRK5 phosphorylates HDAC5 and regulates the HDAC5/Smad3 pathway in renal fibrosis; nuclear-translocated GRK5 upregulates HDAC5, which prevents MEF2A transcriptional activity and represses Smad7, leading to Smad3 activation. GRK5 inhibition attenuates renal fibrosis.","method":"GRK5 overexpression/knockdown in renal cells, nuclear fractionation, HDAC5 and Smad3 pathway Western blot, MEF2A reporter assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pathway analysis with defined molecular intermediates; single lab, single study","pmids":["38206179"],"is_preprint":false},{"year":2025,"finding":"GRK5 inhibition rescues p.Phe508del-CFTR plasma membrane traffic and function in human airway cells; GRK5 siRNA knockdown validated in a genome-wide siRNA screen of >9,000 genes as a regulator of p.Phe508del-CFTR plasma membrane rescue.","method":"Genome-wide siRNA high-content microscopy screen, siRNA validation, functional CFTR assay in primary and immortalized airway cells","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — validated siRNA screen with functional CFTR readout; mechanistic link to CFTR trafficking is established but pathway not fully defined; single study","pmids":["40040803"],"is_preprint":false},{"year":2024,"finding":"GRK5 is required for FPR2 endocytosis: GRK5 phosphorylates FPR2 C-terminal sites enabling β-arrestin recruitment; however, β-arrestin recruitment per se is not essential for FPR2 endocytosis—rather, β-arrestin determines postendocytic delivery to subcellular compartments and the magnitude of downstream ERK signaling.","method":"GRK5-selective pharmacological/genetic manipulation, β-arrestin KO cells, β-arrestin recruitment BRET assay, internalization assay, subcellular trafficking imaging","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological dissection of GRK5 vs. β-arrestin roles with multiple readouts; single lab, multiple orthogonal approaches","pmids":["39706266"],"is_preprint":false},{"year":2018,"finding":"PHLPP2 physically interacts with endogenous GRK5 in neonatal rat ventricular myocytes; PHLPP2 knockdown enhances PE-induced nuclear accumulation of GRK5 and potentiates hypertrophic growth, while PHLPP2 overexpression (requiring phosphatase activity) blocks PE-induced GRK5 nuclear accumulation and hypertrophy in a GRK5-dependent manner.","method":"Co-immunoprecipitation, siRNA knockdown of PHLPP2, adenoviral overexpression, nuclear fractionation, cell size measurement, fetal gene expression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP interaction confirmed plus reciprocal gain/loss-of-function with defined functional readout; single lab, two orthogonal methods","pmids":["29628444"],"is_preprint":false},{"year":2026,"finding":"GRK5 regulates PAR1 desensitization in platelets: GG homozygotes for rs10886430 have ~90% lower GRK5 protein in platelets, leading to reduced PAR1 internalization, elevated platelet responsiveness to thrombin and PAR1 agonist (but not PAR4 agonist), and enhanced thrombus formation in vitro and in vivo. These findings were corroborated in GRK5-/- iPSC-derived megakaryocytes, Grk5-deficient murine platelets, and with GRK5 inhibitor treatment.","method":"Human platelet GRK5 protein quantification in GG vs AA donors, PAR1 internalization assay, platelet activation functional assay, microfluidic endothelialized system, GRK5 KO iPSC-megakaryocytes, Grk5-deficient mouse platelets, murine arterial thrombosis model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal model systems (human platelets, iPSC-MK, mouse KO, pharmacological inhibition, in vivo thrombosis) all converging on PAR1 desensitization mechanism","pmids":["41557909"],"is_preprint":false},{"year":2007,"finding":"GRK5 forms a protein complex with the GABA(B2) subunit of GABA(B) receptors at the plasma membrane (demonstrated by FRET between GRK5 and GB2R-Venus, confirmed by co-immunoprecipitation), mediating desensitization of GABA(B) receptor-operated K+ currents upon repeated baclofen application.","method":"FRET (cerulean/Venus fluorophores), co-immunoprecipitation, Xenopus oocyte electrophysiology, BHK cell coexpression","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET and co-IP with functional desensitization readout; single lab, two orthogonal methods","pmids":["17013811"],"is_preprint":false},{"year":2014,"finding":"CB1 receptor signaling in smooth muscle proceeds via GRK5 phosphorylation (not Gβγ): kinase-deficient GRK5(K215R) abolishes CB1 receptor internalization and ERK1/2/Src kinase activation; β-arrestin1/2 siRNA abolishes ERK1/2 activity; GRK5/β-arrestin-activated ERK1/2 phosphorylates RGS4 at Ser103/Ser108 to accelerate Gαq inactivation and inhibit muscle contraction.","method":"Kinase-deficient GRK5 K215R expression, β-arrestin siRNA, CB1 receptor internalization assay, ERK1/2 activity assay, RGS4 phosphorylation assay, RGS4 mutant (S103A/S108A), contraction assay","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — kinase-dead mutant, siRNA epistasis, substrate site mutagenesis, and functional contraction readout; single lab, multiple orthogonal methods","pmids":["24407588"],"is_preprint":false}],"current_model":"GRK5 is a serine/threonine kinase that constitutively associates with the plasma membrane via a C-terminal amphipathic helix and phosphorylates agonist-occupied GPCRs (including β2AR, rhodopsin, muscarinic, neurotensin, FPR2, and CB1 receptors) to initiate desensitization; its activity is activated by phospholipid-stimulated autophosphorylation at Ser484/Thr485 and inhibited by PKC phosphorylation of C-terminal sites, actin binding (at the N-terminus), and by Ca2+/calmodulin, which binds both N- and C-terminal helices to simultaneously inhibit receptor phosphorylation and disrupt membrane association, thereby triggering GRK5 nuclear translocation where it acts in a kinase-independent manner as a direct DNA-binding co-activator of NFAT and NF-κB to drive pathological cardiac hypertrophic gene transcription, and also phosphorylates non-GPCR substrates including HDAC5, moesin (Thr66), the mineralocorticoid receptor, β-arrestin1 (Ser412), and PAR1, integrating canonical receptor desensitization with non-canonical nuclear signaling in the heart, vasculature, neurons, and other tissues."},"narrative":{"mechanistic_narrative":"GRK5 is a membrane-associated serine/threonine kinase that phosphorylates agonist-occupied G protein-coupled receptors to initiate desensitization, and it doubles as a calcium-gated nuclear transcriptional regulator [PMID:8120045, PMID:8288567, PMID:25332207]. Unlike β-adrenergic receptor kinase, GRK5 phosphorylates rhodopsin in a light-dependent manner, is not activated by Gβγ, lacks an isoprenylation site, and instead remains constitutively associated with the plasma membrane [PMID:7685906, PMID:8120045, PMID:8288567, PMID:18034461]. Membrane targeting and full catalytic competence depend on a C-terminal amphipathic helix and on phospholipid-stimulated autophosphorylation at Ser484/Thr485, while a hydrophobic dimerization interface in the RGS homology domain further supports plasma membrane localization [PMID:8144599, PMID:14976207, PMID:24807909]. GRK5 phosphorylates a broad panel of receptors—β2AR, m2 muscarinic, rhodopsin, neurotensin receptor 1, FPR2, CB1, and PAR1—forming a dynamic complex with agonist-occupied β2AR, and its receptor engagement controls desensitization, internalization, and the balance of β-arrestin-dependent signaling [PMID:8120045, PMID:8288567, PMID:26120872, PMID:28431242, PMID:39706266, PMID:24407588, PMID:41557909]. Its activity is negatively tuned by PKC phosphorylation of the C-terminus and by N-terminal actin binding, and is gated by Ca2+/calmodulin, which binds independent helical regions at the N- and C-termini to simultaneously block receptor phosphorylation, disrupt membrane association, and drive nuclear translocation while activating phosphorylation of soluble substrates [PMID:9013639, PMID:9685424, PMID:31337679, PMID:33321095]. In the nucleus GRK5 binds DNA directly via an NLS-containing region and acts in a kinase-independent manner as a co-activator of NFAT and NF-κB to drive pathological cardiac hypertrophic gene transcription and cardiac fibroblast activation [PMID:23658733, PMID:25332207, PMID:24174526, PMID:33500351]. Beyond GPCRs, GRK5 phosphorylates moesin, the cardiac mineralocorticoid receptor, β-arrestin1, HDAC5, and HDAC6, linking it to cancer cell migration, mineralocorticoid receptor repression, and fibrotic and metabolic programs [PMID:24755472, PMID:32326036, PMID:19661922, PMID:37520700, PMID:38206179, PMID:39779910]. A common GRK5 Q41L polymorphism enhances β-adrenergic desensitization and protects against catecholamine-induced cardiomyopathy [PMID:18425130].","teleology":[{"year":1993,"claim":"Established GRK5 as a distinct GRK family member by showing it phosphorylates rhodopsin light-dependently without Gβγ activation or isoprenylation, distinguishing its membrane-targeting mechanism from βARK.","evidence":"Baculovirus/Sf9 overexpression with in vitro kinase assay and sequence analysis","pmids":["7685906"],"confidence":"High","gaps":["Membrane-association mechanism not yet defined","Physiological GPCR substrates beyond rhodopsin not addressed"]},{"year":1994,"claim":"Defined GRK5 as a broad receptor kinase acting on β2AR, m2 muscarinic, and rhodopsin, mapped autophosphorylation to Ser484/Thr485, and showed constitutive membrane association rather than agonist-triggered translocation.","evidence":"Sf9 purification, in vitro kinase and autophosphorylation site mapping","pmids":["8120045","8288567"],"confidence":"High","gaps":["Functional role of autophosphorylation not yet established","Membrane-targeting motif unidentified"]},{"year":1994,"claim":"Showed phospholipid-stimulated autophosphorylation at Ser484/Thr485 activates the kinase, linking lipid sensing to catalytic competence.","evidence":"In vitro kinase assay with S484A/T485A mutant and phospholipid binding","pmids":["8144599"],"confidence":"High","gaps":["Structural basis of autophosphorylation across the catalytic cleft unknown"]},{"year":1997,"claim":"Identified PKC phosphorylation of the C-terminus as a negative regulatory input that lowers receptor phosphorylation and membrane binding without affecting phospholipid binding.","evidence":"In vitro PKC phosphorylation, intact-cell PMA treatment, kinetic and membrane-binding analysis","pmids":["9013639"],"confidence":"High","gaps":["In vivo significance of PKC crosstalk not established"]},{"year":1998,"claim":"Revealed N-terminal actin binding as an inhibitory mechanism and calmodulin as a switch that displaces GRK5 from actin to permit soluble-substrate phosphorylation.","evidence":"In vitro binding/kinase assays with N-terminal mutagenesis and measured Kd values","pmids":["9685424"],"confidence":"High","gaps":["Cellular consequence of actin/CaM switching not yet tested"]},{"year":2002,"claim":"First implicated nuclear GRK5 in disease by showing it accumulates in the nucleus of hypertensive heart-failure-prone cardiomyocytes, hinting at a non-receptor role.","evidence":"Subcellular fractionation and confocal co-localization in SHHF vs WKY myocytes","pmids":["12052842"],"confidence":"Medium","gaps":["No functional consequence of nuclear localization tested","Single rat model, no causal manipulation"]},{"year":2004,"claim":"Identified a C-terminal amphipathic helix (aa 546–565) as the determinant of plasma membrane localization and lipid-dependent activity.","evidence":"GFP-fusion live-cell imaging with hydrophobic-residue mutagenesis and autophosphorylation assay","pmids":["14976207"],"confidence":"High","gaps":["Whether other regions contribute to membrane binding not resolved"]},{"year":2007,"claim":"Established GRK5 as constitutively pre-associated with β2AR at the membrane and extended its desensitization role to GABA(B) receptors.","evidence":"BRET2/FRET co-localization, cell-free membrane phosphorylation, GRK immunodepletion, oocyte electrophysiology","pmids":["18034461","17013811"],"confidence":"Medium","gaps":["Pre-coupling stoichiometry and dynamics not quantified","GABA(B) interaction not structurally defined"]},{"year":2008,"claim":"Linked a GRK5 coding polymorphism (Q41L) to enhanced β-adrenergic desensitization and cardioprotection, demonstrating physiological consequence of GRK5 activity variation.","evidence":"Transfected cell functional assays, transgenic mice, catecholamine challenge","pmids":["18425130"],"confidence":"High","gaps":["Molecular mechanism of the L41 gain-of-function not fully defined"]},{"year":2009,"claim":"Expanded GRK5 substrate scope beyond receptors to β-arrestin1 (Ser412) and to selective regulation of presynaptic M2/M4 autoreceptor desensitization in neurons.","evidence":"Co-IP, phosphorylation/mutagenesis with ERK readout; GRK5 KO hippocampal slices with pharmacological rescue","pmids":["19661922","19478075"],"confidence":"High","gaps":["Generality of β-arrestin1 phosphorylation across receptors unknown","Behavioral consequences of cholinergic deficit not addressed"]},{"year":2011,"claim":"Defined a kinase-independent cytoskeletal/membrane-remodeling function: GRK5 bundles F-actin and shapes neuronal dendrites and spines, with KO mice showing learning/memory deficits.","evidence":"Domain mutagenesis, in vitro actin bundling, live imaging, GRK5 KO mouse behavior/morphology","pmids":["21930777"],"confidence":"High","gaps":["Relationship between actin function and nuclear/receptor functions unclear"]},{"year":2013,"claim":"Established the mechanistic basis of nuclear GRK5 action: an NLS/CaM-dependent DNA-binding region plus an NES enabling Ca2+/CaM-regulated nucleocytoplasmic shuttling, and direct upregulation of NF-κB transcription in cardiomyocytes.","evidence":"Chimera/mutagenesis, in vitro DNA binding, localization imaging; adenoviral/siRNA NF-κB reporter, EMSA, NLS mutant","pmids":["23658733","24174526"],"confidence":"High","gaps":["DNA sequence specificity of GRK5 binding not defined","Direct NF-κB target genes not enumerated"]},{"year":2014,"claim":"Demonstrated nuclear GRK5 drives NFAT-dependent hypertrophic transcription via direct DNA binding without phosphorylation, with epistasis through NFATc3 establishing it as a transcriptional co-activator in heart disease.","evidence":"NFAT-luciferase, transgenic/KO mouse TAC, adenoviral transfer, NFATc3 KO epistasis","pmids":["25332207"],"confidence":"High","gaps":["Whether GRK5 contacts NFAT directly or via shared DNA elements not fully resolved"]},{"year":2014,"claim":"Extended GRK5 kinase substrates to moesin (Thr66), linking it to cytoskeletal/focal-adhesion regulation and prostate cancer cell motility.","evidence":"MS phosphoproteomics, in vitro kinase, T66 mutagenesis, siRNA, xenograft","pmids":["24755472"],"confidence":"High","gaps":["Upstream signal triggering moesin phosphorylation not defined"]},{"year":2014,"claim":"Showed RGS-domain dimerization (HDI region) supports membrane localization and PAR1-coupled calcium regulation, adding self-association to GRK5's membrane-targeting repertoire.","evidence":"Chimeras, point mutagenesis (M165E/F166E), co-IP, FRET, calcium release assay","pmids":["24807909"],"confidence":"Medium","gaps":["Physiological prevalence and regulation of dimerization unknown"]},{"year":2014,"claim":"Established a GRK5-dependent, kinase-required CB1 receptor signaling route through β-arrestin to ERK and RGS4 phosphorylation controlling smooth muscle contraction.","evidence":"GRK5 K215R, β-arrestin siRNA epistasis, RGS4 site mutagenesis, contraction assay","pmids":["24407588"],"confidence":"High","gaps":["Tissue generality of the CB1-GRK5-RGS4 axis untested"]},{"year":2015,"claim":"Provided structural and biochemical mechanisms: a 1.8 Å full-length structure explaining cis-autophosphorylation, and nanodisc reconstitution showing GRK5 phosphorylates NTSR1 activation-independently with lipid-dependent regiospecificity distinct from GRK2.","evidence":"X-ray crystallography; nanodisc in vitro phosphorylation with MS site mapping and NTSR1 mutants","pmids":["26032409","26120872"],"confidence":"High","gaps":["Conformational changes during receptor engagement not captured by static structure"]},{"year":2017,"claim":"Defined the dynamic GRK5–β2AR engagement, mapping receptor contacts to the RH bundle, membrane-binding surface, and catalytic cleft and revealing large interdomain rearrangements.","evidence":"XL-MS, HDX-MS, EM, mutagenesis, MD simulations, docking","pmids":["28431242"],"confidence":"High","gaps":["High-resolution receptor-bound structure still lacking"]},{"year":2019,"claim":"Clarified how Ca2+·CaM allosterically inhibits receptor phosphorylation while activating soluble-substrate phosphorylation, and showed a chemical probe (malbrancheamide) can block GRK5 nuclear translocation and hypertrophy.","evidence":"SAXS, negative-stain EM, natural-product probe, in-cell translocation and hypertrophy assays","pmids":["31337679"],"confidence":"High","gaps":["Selectivity and in vivo efficacy of the probe not established"]},{"year":2020,"claim":"Resolved the CaM-GRK5 structure showing independent N- and C-domain engagement that separates membrane disruption (translocation) from kinase activation, unifying the calcium-gated localization switch.","evidence":"Cryo-EM/crystal structure, MD, kinase assays, localization experiments","pmids":["33321095"],"confidence":"High","gaps":["In-cell kinetics of the CaM-driven switch under physiological calcium not measured"]},{"year":2020,"claim":"Extended GRK5 cardiac substrates and partners to the mineralocorticoid receptor (repression upon β2AR activation) and the β1AR-SAP97-CaMKII complex, broadening its cardiomyocyte signaling roles.","evidence":"CRISPR KO/overexpression, co-IP, MR reporter; cardiac-specific conditional KO with co-IP and CaMKII activity","pmids":["32326036","32507058"],"confidence":"Medium","gaps":["MR phosphosites not mapped","Direct vs indirect effects on the β1AR-SAP97 complex unresolved"]},{"year":2021,"claim":"Demonstrated nuclear GRK5 drives cardiac fibroblast activation and that a CaM-binding peptide inhibitor (GRK5nt) blocks nuclear accumulation and pathological NFAT/NF-κB transcription, providing a therapeutic proof-of-concept.","evidence":"Fibroblast-specific KO with AngII/MI models; GRK5nt adenoviral/transgenic mice, TAC, CaM co-IP, reporters","pmids":["33500351","33785612"],"confidence":"High","gaps":["Fibroblast nuclear GRK5 transcriptional targets not enumerated","GRK5nt pharmacokinetics/specificity untested"]},{"year":2022,"claim":"Refined receptor-level selectivity (Gq determines GRK2/3 vs GRK5/6 usage at AT1R) and revealed that catalytic activity is required for cardiac homeostasis, since catalytic-dead K215R mice develop dysfunction and fibrosis.","evidence":"GRK inhibition/KO with β-arrestin recruitment and single-molecule imaging; K215R knock-in mice with echocardiography/histology","pmids":["35078997","35540100"],"confidence":"High","gaps":["How nuclear-restricted catalytic-dead GRK5 raises p53 mechanistically unclear","Generality of Gq-gated selectivity across receptors limited"]},{"year":2024,"claim":"Broadened GRK5's substrate/regulatory network to HDAC family kinases—HDAC6 in chondrocytes (downstream of KLF9) and HDAC5/Smad3 in renal fibrosis—and to FPR2 endocytic control, linking GRK5 to osteoarthritis, renal fibrosis, and trafficking.","evidence":"ChIP/luciferase, co-IP, phosphorylation and rescue assays (HDAC6); overexpression/knockdown with pathway Western and MEF2A reporter (HDAC5); GRK5/β-arrestin genetic dissection of FPR2 trafficking","pmids":["39779910","38206179","39706266"],"confidence":"Medium","gaps":["Direct HDAC phosphosites not all mapped","Whether these are kinase-dependent or nuclear scaffolding roles partly unresolved"]},{"year":2025,"claim":"Connected GRK5 to CFTR rescue and refined its β-cell metabolic role, identifying GRK5 as a regulator of p.Phe508del-CFTR plasma membrane trafficking and of HDAC5/immediate-early-gene programs supporting β-cell mass.","evidence":"Genome-wide siRNA screen with CFTR functional validation; β-cell-specific Grk5 KO with GTT, β-cell mass, RNA-seq, HDAC5 phosphorylation","pmids":["40040803","37520700"],"confidence":"Medium","gaps":["GRK5-CFTR mechanistic pathway undefined","Direct β-cell GRK5 substrate driving IEG program not pinned down"]},{"year":2026,"claim":"Established a clinically relevant GRK5 role in hemostasis: low platelet GRK5 (via rs10886430) impairs PAR1 desensitization, increasing thrombin responsiveness and thrombus formation.","evidence":"Human platelet quantification, PAR1 internalization/activation assays, microfluidics, GRK5 KO iPSC-megakaryocytes, Grk5-deficient mouse platelets, in vivo thrombosis","pmids":["41557909"],"confidence":"High","gaps":["PAR1 phosphosites targeted by GRK5 in platelets not mapped","Selectivity over PAR4 mechanism not fully explained"]},{"year":null,"claim":"How the membrane-receptor kinase, cytoskeletal, and nuclear DNA-binding/transcriptional functions of GRK5 are coordinately partitioned in a given cell, and the DNA sequence specificity of nuclear GRK5, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No genome-wide map of nuclear GRK5 DNA occupancy","Quantitative rules governing receptor- vs nuclear-pool allocation unknown","Direct vs cofactor-mediated transcriptional contacts for NFAT/NF-κB undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,8,14,16,33,37]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[13,14]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[13,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,5,9]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[4,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,5,6,19]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,11,13,24]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[4,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[20,21]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,18,26,33,37]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,13,24,35]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[35]}],"complexes":[],"partners":["ADRB2","ARRB1","CALM1","ACTB","NR3C2","PHLPP2","SAP97","HDAC5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P34947","full_name":"G protein-coupled receptor kinase 5","aliases":["G protein-coupled receptor kinase GRK5"],"length_aa":590,"mass_kda":67.8,"function":"Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro)","subcellular_location":"Cytoplasm; Nucleus; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P34947/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GRK5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GRK5","total_profiled":1310},"omim":[{"mim_id":"607315","title":"CALCIUM-BINDING PROTEIN 5; CABP5","url":"https://www.omim.org/entry/607315"},{"mim_id":"607314","title":"CALCIUM-BINDING PROTEIN 2; CABP2","url":"https://www.omim.org/entry/607314"},{"mim_id":"605563","title":"CALCIUM-BINDING PROTEIN 1; CABP1","url":"https://www.omim.org/entry/605563"},{"mim_id":"600870","title":"G PROTEIN-COUPLED RECEPTOR KINASE 5; GRK5","url":"https://www.omim.org/entry/600870"},{"mim_id":"600869","title":"G PROTEIN-COUPLED RECEPTOR KINASE 6; GRK6","url":"https://www.omim.org/entry/600869"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GRK5"},"hgnc":{"alias_symbol":[],"prev_symbol":["GPRK5"]},"alphafold":{"accession":"P34947","domains":[{"cath_id":"1.10.167.10","chopping":"53-157","consensus_level":"high","plddt":95.9355,"start":53,"end":157},{"cath_id":"3.30.200.20","chopping":"181-268_478-519","consensus_level":"medium","plddt":93.7163,"start":181,"end":519},{"cath_id":"1.10.510.10","chopping":"271-459","consensus_level":"high","plddt":96.4557,"start":271,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P34947","model_url":"https://alphafold.ebi.ac.uk/files/AF-P34947-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P34947-F1-predicted_aligned_error_v6.png","plddt_mean":90.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GRK5","jax_strain_url":"https://www.jax.org/strain/search?query=GRK5"},"sequence":{"accession":"P34947","fasta_url":"https://rest.uniprot.org/uniprotkb/P34947.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P34947/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P34947"}},"corpus_meta":[{"pmid":"18425130","id":"PMC_18425130","title":"A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.","date":"2008","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18425130","citation_count":264,"is_preprint":false},{"pmid":"8120045","id":"PMC_8120045","title":"Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8120045","citation_count":161,"is_preprint":false},{"pmid":"7685906","id":"PMC_7685906","title":"Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7685906","citation_count":144,"is_preprint":false},{"pmid":"28431242","id":"PMC_28431242","title":"Structural and Functional Analysis of a β2-Adrenergic Receptor Complex with GRK5.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28431242","citation_count":139,"is_preprint":false},{"pmid":"9013639","id":"PMC_9013639","title":"Regulation of the G protein-coupled receptor kinase GRK5 by protein kinase C.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9013639","citation_count":110,"is_preprint":false},{"pmid":"8288567","id":"PMC_8288567","title":"Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8288567","citation_count":95,"is_preprint":false},{"pmid":"8144599","id":"PMC_8144599","title":"Phospholipid-stimulated autophosphorylation activates the G protein-coupled receptor kinase GRK5.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8144599","citation_count":87,"is_preprint":false},{"pmid":"35078997","id":"PMC_35078997","title":"Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35078997","citation_count":86,"is_preprint":false},{"pmid":"11641430","id":"PMC_11641430","title":"Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11641430","citation_count":77,"is_preprint":false},{"pmid":"14976207","id":"PMC_14976207","title":"A predicted amphipathic helix mediates plasma membrane localization of GRK5.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14976207","citation_count":75,"is_preprint":false},{"pmid":"25332207","id":"PMC_25332207","title":"GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/25332207","citation_count":70,"is_preprint":false},{"pmid":"12052842","id":"PMC_12052842","title":"Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats.","date":"2002","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/12052842","citation_count":70,"is_preprint":false},{"pmid":"17011668","id":"PMC_17011668","title":"GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment.","date":"2006","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/17011668","citation_count":65,"is_preprint":false},{"pmid":"19661922","id":"PMC_19661922","title":"Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19661922","citation_count":60,"is_preprint":false},{"pmid":"21127457","id":"PMC_21127457","title":"Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.","date":"2011","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21127457","citation_count":50,"is_preprint":false},{"pmid":"33500351","id":"PMC_33500351","title":"GRK5 is a regulator of fibroblast activation and cardiac fibrosis.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33500351","citation_count":49,"is_preprint":false},{"pmid":"24755472","id":"PMC_24755472","title":"G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24755472","citation_count":49,"is_preprint":false},{"pmid":"9685424","id":"PMC_9685424","title":"Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9685424","citation_count":45,"is_preprint":false},{"pmid":"26829117","id":"PMC_26829117","title":"\"Canonical and non-canonical actions of GRK5 in the heart\".","date":"2016","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26829117","citation_count":44,"is_preprint":false},{"pmid":"24174526","id":"PMC_24174526","title":"Regulation of nuclear factor κB (NF-κB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5).","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24174526","citation_count":44,"is_preprint":false},{"pmid":"9495886","id":"PMC_9495886","title":"Sequestration of human muscarinic acetylcholine receptor hm1-hm5 subtypes: effect of G protein-coupled receptor kinases GRK2, GRK4, GRK5 and GRK6.","date":"1998","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9495886","citation_count":44,"is_preprint":false},{"pmid":"26120872","id":"PMC_26120872","title":"G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5) Exhibit Selective Phosphorylation of the Neurotensin Receptor in Vitro.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26120872","citation_count":42,"is_preprint":false},{"pmid":"33560342","id":"PMC_33560342","title":"G protein-coupled receptor kinase 5 (GRK5) contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33560342","citation_count":41,"is_preprint":false},{"pmid":"29463786","id":"PMC_29463786","title":"GRK5 functions as an oncogenic factor in non-small-cell lung cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29463786","citation_count":38,"is_preprint":false},{"pmid":"26032409","id":"PMC_26032409","title":"Atomic Structure of GRK5 Reveals Distinct Structural Features Novel for G Protein-coupled Receptor Kinases.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26032409","citation_count":36,"is_preprint":false},{"pmid":"19478075","id":"PMC_19478075","title":"GRK5 deficiency leads to reduced hippocampal acetylcholine level via impaired presynaptic M2/M4 autoreceptor desensitization.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19478075","citation_count":35,"is_preprint":false},{"pmid":"22389501","id":"PMC_22389501","title":"Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22389501","citation_count":33,"is_preprint":false},{"pmid":"31696655","id":"PMC_31696655","title":"GRK5 Inhibition Attenuates Cartilage Degradation via Decreased NF-κB Signaling.","date":"2020","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/31696655","citation_count":32,"is_preprint":false},{"pmid":"17013811","id":"PMC_17013811","title":"Desensitization of GABA(B) receptor signaling by formation of protein complexes of GABA(B2) subunit with GRK4 or GRK5.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17013811","citation_count":32,"is_preprint":false},{"pmid":"33321095","id":"PMC_33321095","title":"Structure of a GRK5-Calmodulin Complex Reveals Molecular Mechanism of GRK Activation and Substrate Targeting.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33321095","citation_count":31,"is_preprint":false},{"pmid":"23658733","id":"PMC_23658733","title":"Distinct structural features of G protein-coupled receptor kinase 5 (GRK5) regulate its nuclear localization and DNA-binding ability.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23658733","citation_count":31,"is_preprint":false},{"pmid":"21041302","id":"PMC_21041302","title":"GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21041302","citation_count":30,"is_preprint":false},{"pmid":"22753221","id":"PMC_22753221","title":"Parallel changes in neuronal AT1R and GRK5 expression following exercise training in heart failure.","date":"2012","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/22753221","citation_count":29,"is_preprint":false},{"pmid":"32326036","id":"PMC_32326036","title":"Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32326036","citation_count":29,"is_preprint":false},{"pmid":"34219377","id":"PMC_34219377","title":"Circ_0001821 knockdown suppresses growth, metastasis, and TAX resistance of non-small-cell lung cancer cells by regulating the miR-526b-5p/GRK5 axis.","date":"2021","source":"Pharmacology research & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/34219377","citation_count":29,"is_preprint":false},{"pmid":"30618771","id":"PMC_30618771","title":"GRK5 - A Functional Bridge Between Cardiovascular and Neurodegenerative Disorders.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30618771","citation_count":28,"is_preprint":false},{"pmid":"23111327","id":"PMC_23111327","title":"GRK5 ablation contributes to insulin resistance.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23111327","citation_count":28,"is_preprint":false},{"pmid":"21930777","id":"PMC_21930777","title":"GRK5 promotes F-actin bundling and targets bundles to membrane structures to control neuronal morphogenesis.","date":"2011","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21930777","citation_count":27,"is_preprint":false},{"pmid":"18034461","id":"PMC_18034461","title":"Phosphorylation of the beta2-adrenergic receptor in plasma membranes by intrinsic GRK5.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18034461","citation_count":27,"is_preprint":false},{"pmid":"23693024","id":"PMC_23693024","title":"G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells.","date":"2013","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/23693024","citation_count":25,"is_preprint":false},{"pmid":"32507058","id":"PMC_32507058","title":"GRK5 Controls SAP97-Dependent Cardiotoxic β1 Adrenergic Receptor-CaMKII Signaling in Heart Failure.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32507058","citation_count":23,"is_preprint":false},{"pmid":"31337679","id":"PMC_31337679","title":"Perturbation of the interactions of calmodulin with GRK5 using a natural product chemical probe.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31337679","citation_count":23,"is_preprint":false},{"pmid":"30701991","id":"PMC_30701991","title":"GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy.","date":"2019","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/30701991","citation_count":22,"is_preprint":false},{"pmid":"25104355","id":"PMC_25104355","title":"Overlapping and opposing functions of G protein-coupled receptor kinase 2 (GRK2) and GRK5 during heart development.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25104355","citation_count":22,"is_preprint":false},{"pmid":"18522748","id":"PMC_18522748","title":"GRK5 deficiency exaggerates inflammatory changes in TgAPPsw mice.","date":"2008","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/18522748","citation_count":22,"is_preprint":false},{"pmid":"33671974","id":"PMC_33671974","title":"Targeting GRK5 for Treating Chronic Degenerative Diseases.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671974","citation_count":21,"is_preprint":false},{"pmid":"24598771","id":"PMC_24598771","title":"GRK5 dysfunction accelerates tau hyperphosphorylation in APP (swe) mice through impaired cholinergic activity.","date":"2014","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/24598771","citation_count":20,"is_preprint":false},{"pmid":"19842931","id":"PMC_19842931","title":"GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19842931","citation_count":20,"is_preprint":false},{"pmid":"24407588","id":"PMC_24407588","title":"Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase.","date":"2014","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24407588","citation_count":19,"is_preprint":false},{"pmid":"16041172","id":"PMC_16041172","title":"Chronic beta-adrenergic receptor stimulation enhances the expression of G-Protein coupled receptor kinases, GRK2 and GRK5, in both the heart and peripheral lymphocytes.","date":"2005","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/16041172","citation_count":19,"is_preprint":false},{"pmid":"31664083","id":"PMC_31664083","title":"Downregulation of GRK5 hampers the migration of breast cancer cells.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31664083","citation_count":18,"is_preprint":false},{"pmid":"30511419","id":"PMC_30511419","title":"GRK5 influences the phosphorylation of tau via GSK3β and contributes to Alzheimer's disease.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30511419","citation_count":18,"is_preprint":false},{"pmid":"27326393","id":"PMC_27326393","title":"Dual role of GRK5 in cancer development and progression.","date":"2016","source":"Translational medicine @ UniSa","url":"https://pubmed.ncbi.nlm.nih.gov/27326393","citation_count":17,"is_preprint":false},{"pmid":"30060048","id":"PMC_30060048","title":"GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence.","date":"2018","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30060048","citation_count":17,"is_preprint":false},{"pmid":"24807909","id":"PMC_24807909","title":"The regulator of G protein signaling (RGS) domain of G protein-coupled receptor kinase 5 (GRK5) regulates plasma membrane localization and function.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/24807909","citation_count":17,"is_preprint":false},{"pmid":"10448093","id":"PMC_10448093","title":"Enhanced GRK5 expression in the hearts of cardiomyopathic hamsters, J2N-k.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10448093","citation_count":16,"is_preprint":false},{"pmid":"18955119","id":"PMC_18955119","title":"Augmented axonal defects and synaptic degenerative changes in female GRK5 deficient mice.","date":"2008","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/18955119","citation_count":16,"is_preprint":false},{"pmid":"22507984","id":"PMC_22507984","title":"GRK5 deficiency decreases diet-induced obesity and adipogenesis.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22507984","citation_count":15,"is_preprint":false},{"pmid":"29628444","id":"PMC_29628444","title":"PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29628444","citation_count":15,"is_preprint":false},{"pmid":"24594703","id":"PMC_24594703","title":"GRK5 intronic (CA)n polymorphisms associated with type 2 diabetes in Chinese Hainan Island.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24594703","citation_count":15,"is_preprint":false},{"pmid":"29543709","id":"PMC_29543709","title":"The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium-Calmodulin Dependent Transcription Factors.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29543709","citation_count":15,"is_preprint":false},{"pmid":"7789183","id":"PMC_7789183","title":"Chromosomal mapping of the genes GPRK5 and GPRK6 encoding G protein-coupled receptor kinases GRK5 and GRK6.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7789183","citation_count":14,"is_preprint":false},{"pmid":"32856617","id":"PMC_32856617","title":"KR-39038, a Novel GRK5 Inhibitor, Attenuates Cardiac Hypertrophy and Improves Cardiac Function in Heart Failure.","date":"2020","source":"Biomolecules & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32856617","citation_count":14,"is_preprint":false},{"pmid":"26066465","id":"PMC_26066465","title":"Categorical complexities of Plasmodium falciparum malaria in individuals is associated with genetic variations in ADORA2A and GRK5 genes.","date":"2015","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26066465","citation_count":14,"is_preprint":false},{"pmid":"28334166","id":"PMC_28334166","title":"GRK5 Regulates Social Behavior Via Suppression of mTORC1 Signaling in Medial Prefrontal Cortex.","date":"2018","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/28334166","citation_count":13,"is_preprint":false},{"pmid":"36055000","id":"PMC_36055000","title":"Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36055000","citation_count":12,"is_preprint":false},{"pmid":"25638254","id":"PMC_25638254","title":"Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25638254","citation_count":12,"is_preprint":false},{"pmid":"29069820","id":"PMC_29069820","title":"The influence of two functional genetic variants of GRK5 on tau phosphorylation and their association with Alzheimer's disease risk.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069820","citation_count":12,"is_preprint":false},{"pmid":"35540100","id":"PMC_35540100","title":"Genetic Catalytic Inactivation of GRK5 Impairs Cardiac Function in Mice Via Dysregulated P53 Levels.","date":"2022","source":"JACC. Basic to translational science","url":"https://pubmed.ncbi.nlm.nih.gov/35540100","citation_count":11,"is_preprint":false},{"pmid":"37380112","id":"PMC_37380112","title":"TRPA1 deficiency attenuates cardiac fibrosis via regulating GRK5/NFAT signaling in diabetic rats.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37380112","citation_count":10,"is_preprint":false},{"pmid":"33785612","id":"PMC_33785612","title":"A peptide of the N terminus of GRK5 attenuates pressure-overload hypertrophy and heart failure.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/33785612","citation_count":10,"is_preprint":false},{"pmid":"26248277","id":"PMC_26248277","title":"β2- and β1-Adrenoceptor Expression Exhibits a Common Regulatory Pattern With GRK2 and GRK5 in Human and Animal Models of Cardiovascular Diseases.","date":"2015","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26248277","citation_count":10,"is_preprint":false},{"pmid":"29663513","id":"PMC_29663513","title":"A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.","date":"2018","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/29663513","citation_count":10,"is_preprint":false},{"pmid":"14691047","id":"PMC_14691047","title":"Endosome sorting of beta 2-adrenoceptors is GRK5 independent.","date":"2003","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14691047","citation_count":10,"is_preprint":false},{"pmid":"39779910","id":"PMC_39779910","title":"KLF9-GRK5-HDAC6 axis aggravates osteoarthritis pathogenesis by promoting chondrocyte extracellular matrix degradation and apoptosis.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39779910","citation_count":9,"is_preprint":false},{"pmid":"26778781","id":"PMC_26778781","title":"GRK5 deficiency leads to susceptibility to intermittent hypoxia-induced cognitive impairment.","date":"2016","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26778781","citation_count":9,"is_preprint":false},{"pmid":"27193825","id":"PMC_27193825","title":"GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27193825","citation_count":9,"is_preprint":false},{"pmid":"38206179","id":"PMC_38206179","title":"GRK5 promoted renal fibrosis via HDAC5/Smad3 signaling pathway.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38206179","citation_count":8,"is_preprint":false},{"pmid":"33838258","id":"PMC_33838258","title":"Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/33838258","citation_count":8,"is_preprint":false},{"pmid":"22078319","id":"PMC_22078319","title":"Overlapping and distinct roles of GRK5 in TLR2-, and TLR3-induced inflammatory response in vivo.","date":"2011","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22078319","citation_count":8,"is_preprint":false},{"pmid":"18855542","id":"PMC_18855542","title":"Protective effect of a GRK5 polymorphism on heart failure and its interaction with beta-adrenergic receptor antagonists.","date":"2008","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/18855542","citation_count":8,"is_preprint":false},{"pmid":"34268929","id":"PMC_34268929","title":"Association between gene polymorphism of GRK5 and breast cancer risk in Chinese population.","date":"2021","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34268929","citation_count":7,"is_preprint":false},{"pmid":"30784280","id":"PMC_30784280","title":"GRK5 promotes tumor progression in renal cell carcinoma.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30784280","citation_count":7,"is_preprint":false},{"pmid":"25732260","id":"PMC_25732260","title":"Involvement of NFκB signaling in mediating the effects of GRK5 on neural stem cells.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25732260","citation_count":7,"is_preprint":false},{"pmid":"37520700","id":"PMC_37520700","title":"Type 2 diabetes susceptibility gene GRK5 regulates physiological pancreatic β-cell proliferation via phosphorylation of HDAC5.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37520700","citation_count":6,"is_preprint":false},{"pmid":"32363002","id":"PMC_32363002","title":"Characterization of GRK5 as a novel regulator of rhabdomyosarcoma tumor cell growth and self-renewal.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/32363002","citation_count":6,"is_preprint":false},{"pmid":"39033880","id":"PMC_39033880","title":"Porphyromonas gingivalis virulence factors induce toxic effects in SH-SY5Y neuroblastoma cells: GRK5 modulation as a protective strategy.","date":"2024","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39033880","citation_count":6,"is_preprint":false},{"pmid":"26235218","id":"PMC_26235218","title":"GRK5 Polymorphisms and Postoperative Atrial Fibrillation following Coronary Artery Bypass Graft Surgery.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26235218","citation_count":6,"is_preprint":false},{"pmid":"39706266","id":"PMC_39706266","title":"GRK5 regulates endocytosis of FPR2 independent of β-arrestins.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39706266","citation_count":5,"is_preprint":false},{"pmid":"34958040","id":"PMC_34958040","title":"GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer's Disease.","date":"2022","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/34958040","citation_count":5,"is_preprint":false},{"pmid":"27565865","id":"PMC_27565865","title":"GRK5-Knockout Mice Generated by TALEN-Mediated Gene Targeting.","date":"2016","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/27565865","citation_count":5,"is_preprint":false},{"pmid":"36633120","id":"PMC_36633120","title":"GRK5-mediated inflammation and fibrosis exert cardioprotective effects during the acute phase of myocardial infarction.","date":"2023","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/36633120","citation_count":4,"is_preprint":false},{"pmid":"35582468","id":"PMC_35582468","title":"GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone.","date":"2022","source":"World journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35582468","citation_count":4,"is_preprint":false},{"pmid":"41557909","id":"PMC_41557909","title":"Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk.","date":"2026","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/41557909","citation_count":4,"is_preprint":false},{"pmid":"36584571","id":"PMC_36584571","title":"Genetic Arg-304-His substitution in GRK5 protects against sepsis progression by alleviating NF-κB-mediated inflammation.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36584571","citation_count":4,"is_preprint":false},{"pmid":"27618959","id":"PMC_27618959","title":"The analysis of heterotaxy patients reveals new loss-of-function variants of GRK5.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27618959","citation_count":4,"is_preprint":false},{"pmid":"29773828","id":"PMC_29773828","title":"Single Nucleotide Polymorphisms in the G-Protein Coupled Receptor Kinase 5 (GRK5) Gene are associated with Plasma LDL-Cholesterol Levels in Humans.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29773828","citation_count":4,"is_preprint":false},{"pmid":"39838122","id":"PMC_39838122","title":"GRK5 is required for adipocyte differentiation through ERK activation.","date":"2025","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/39838122","citation_count":3,"is_preprint":false},{"pmid":"40040803","id":"PMC_40040803","title":"Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40040803","citation_count":3,"is_preprint":false},{"pmid":"36525154","id":"PMC_36525154","title":"GRK5 Deficiency in the Hippocampus Leads to Cognitive Impairment via Abnormal Microglial Alterations.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36525154","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52891,"output_tokens":10008,"usd":0.154396,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20421,"output_tokens":7549,"usd":0.145415,"stage2_stop_reason":"end_turn"},"total_usd":0.299811,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"GRK5 phosphorylates rhodopsin in a light-dependent manner and is not activated by G-protein βγ subunits, unlike βARK, and does not contain a consensus sequence for isoprenylation, distinguishing it from other GRK family members.\",\n      \"method\": \"Baculovirus/Sf9 overexpression, in vitro kinase assay, sequence analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted kinase assay with purified protein; independently replicated in multiple early biochemical characterization papers (PMIDs 8120045, 8288567)\",\n      \"pmids\": [\"7685906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Purified GRK5 phosphorylates β2-adrenergic receptor, m2 muscarinic receptor, and rhodopsin in an agonist/light-dependent manner; major autophosphorylation sites mapped to Ser484 and Thr485; GRK5 associates with membranes constitutively and does not translocate upon agonist stimulation.\",\n      \"method\": \"Sf9 purification, in vitro kinase assay, peptide phosphorylation, autophosphorylation site mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purified protein in vitro assay with multiple substrates and site mapping; replicated across two independent papers (PMIDs 8120045, 8288567)\",\n      \"pmids\": [\"8120045\", \"8288567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Phospholipid-stimulated autophosphorylation of GRK5 at Ser484 and Thr485 (C-terminal region, aa 489–590 mediates phospholipid interaction) activates GRK5; a non-autophosphorylatable S484A/T485A mutant has ~15–20-fold reduced ability to phosphorylate β2AR and rhodopsin.\",\n      \"method\": \"In vitro kinase assay, mutagenesis (S484A/T485A), GST fusion-protein phospholipid binding, phosphoamino acid analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with defined mutants, mutagenesis, multiple orthogonal methods in one study\",\n      \"pmids\": [\"8144599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PKC phosphorylates GRK5 at two major sites within the C-terminal 26 amino acids, stoichiometrically reducing its ability to phosphorylate rhodopsin (~5-fold increased Km, ~3-fold decreased Vmax) and decreasing its ability to bind rhodopsin-containing membranes, without altering direct phospholipid binding.\",\n      \"method\": \"In vitro PKC phosphorylation assay, intact-cell PMA treatment of COS-1 cells, kinetic analysis, membrane-binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetic analysis plus intact-cell confirmation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9013639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Actin binds and inhibits GRK5: monomeric actin binds with Kd ~0.6 μM and filamentous actin with Kd ~0.2 μM; mutation of 6 N-terminal amino acids eliminates actin-mediated inhibition. Calmodulin (which binds the GRK5 N-terminus) displaces GRK5 from actin, selectively permitting phosphorylation of soluble but not membrane-bound GPCR substrates.\",\n      \"method\": \"In vitro binding assay, in vitro kinase assay, N-terminal mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with binding constants measured and mutagenesis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"9685424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A predicted amphipathic helix (aa 546–565) in the GRK5 C-terminus mediates plasma membrane localization; hydrophobic residues within this helix are necessary for PM targeting of GFP fusion constructs and for phospholipid-dependent autophosphorylation and phosphorylation of membrane-bound rhodopsin.\",\n      \"method\": \"GFP fusion live-cell imaging, mutagenesis of hydrophobic/basic residues, autophosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence validated by mutagenesis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"14976207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GRK5 is constitutively associated with β2AR at the plasma membrane (demonstrated by high basal BRET2 between β2AR-Rluc and GRK5-GFP2 that is not diminished by agonist). Extensively washed plasma membranes retain GRK5 and support agonist-dependent GRK site phosphorylation (pS355/356) of β2AR, while GRK2 is depleted.\",\n      \"method\": \"BRET2 assay, cell-free membrane phosphorylation assay, immunodepletion of GRKs\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — BRET2 co-localization and cell-free assay; single lab, single study\",\n      \"pmids\": [\"18034461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GRK5-Leu41 (Q41L polymorphism) uncouples isoproterenol-stimulated β-adrenergic responses more effectively than GRK5-Gln41 in transfected cells and transgenic mice, providing enhanced βAR desensitization ('genetic beta-blockade') and protecting against catecholamine-induced cardiomyopathy.\",\n      \"method\": \"Transfected cell functional assay, transgenic mouse model, catecholamine challenge model\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional assays in cells and in vivo transgenic model, multiple orthogonal approaches in one study, widely cited\",\n      \"pmids\": [\"18425130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK5 phosphorylates β-arrestin1 at Ser412 when β-arrestin1 is bound to the phosphorylated 5-HT4 receptor C-terminus; this phosphorylated β-arrestin1 prevents activation of Src constitutively bound to the receptor, thereby inhibiting the G protein-independent Src/ERK signaling pathway.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assay, site-directed mutagenesis, ERK activity measurement in HEK-293 cells and neurons\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphorylation site identified biochemically with mutagenesis and functional readout in two cell types; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19661922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GRK5 promotes F-actin bundling and targets bundles to plasma membrane structures via simultaneous interaction with F-actin and phosphatidylinositol-4,5-bisphosphate; separate domains of GRK5 mediate actin cytoskeleton coupling and membrane remodeling, and this function (not kinase activity) is required for neurite outgrowth, dendrite branching, and spine morphogenesis. GRK5 KO mice display immature spine morphology and deficient learning and memory.\",\n      \"method\": \"Domain deletion/mutagenesis, in vitro F-actin bundling assay, live-cell imaging, GRK5 KO mouse behavioral and morphological analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro actin bundling reconstitution plus KO mouse phenotype with morphological readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21930777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In hypertensive heart failure-prone (SHHF) rat cardiomyocytes, GRK5 specifically accumulates in the nucleus (colocalizing with coilin, a component of nuclear substructures involved in RNA synthesis/processing), whereas in normal WKY myocytes it distributes diffusely in the cytoplasm.\",\n      \"method\": \"Subcellular fractionation, fluorescent confocal microscopy, co-localization with nuclear markers\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct localization by fractionation and confocal microscopy; single lab, single study, no direct functional consequence tested\",\n      \"pmids\": [\"12052842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GRK5 contains a nuclear localization sequence (NLS) that also binds DNA in vitro; the DNA-binding ability requires both the NLS and an N-terminal calmodulin-binding site. A functional nuclear export sequence (NES) was identified that mediates Ca2+/CaM-dependent nuclear export. GRK5 nuclear localization is differentially regulated from GRK4 and GRK6 subfamily members.\",\n      \"method\": \"GRK5/GRK4/GRK6 chimera analysis, mutagenesis, in vitro DNA-binding assay, live-cell nuclear localization imaging\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro DNA-binding plus cell localization with mutagenesis; single lab, two orthogonal methods\",\n      \"pmids\": [\"23658733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Nuclear GRK5 increases NF-κB p50 and p65 levels, promotes p65 phosphorylation, increases NF-κB DNA binding activity, and drives NF-κB reporter activity in cardiomyocytes; a nuclear-localization-deficient GRK5 mutant loses these effects, indicating dependence on nuclear translocation.\",\n      \"method\": \"Adenoviral overexpression, siRNA knockdown in NRVMs, NF-κB reporter assay, EMSA, co-immunoprecipitation, nuclear-localization mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple readouts including NLS mutant; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24174526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nuclear GRK5 enhances NFAT-mediated hypertrophic gene transcription in cardiomyocytes via direct DNA binding (without a phosphorylation event); GRK5 transgenic mice show elevated NFAT reporter activity basally and after TAC/PE; GRK5 null mice have reduced NFAT activity after TAC; loss of NFATc3 protects GRK5-overexpressing mice from exaggerated hypertrophy.\",\n      \"method\": \"NFAT-luciferase reporter, transgenic and knockout mouse TAC model, adenoviral gene transfer, molecular DNA-binding studies, epistasis via NFATc3 KO\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple gain/loss-of-function models in cells and mice with epistasis; single lab, multiple orthogonal methods and replicated across experiments\",\n      \"pmids\": [\"25332207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GRK5 phosphorylates moesin at Thr66 (identified by mass spectrometry and confirmed by mutation), regulates moesin subcellular distribution, colocalizes with moesin at the cell periphery, and controls prostate cancer cell migration, invasion, and focal adhesion formation.\",\n      \"method\": \"Mass spectrometric phosphoproteome, in vitro kinase assay, T66 mutagenesis, co-localization imaging, GRK5 siRNA knockdown, xenograft model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphorylation site identified by MS and confirmed by mutagenesis with functional cell assays and in vivo xenograft; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24755472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK5 deficiency selectively impairs desensitization of presynaptic M2/M4 muscarinic autoreceptors (not M1 receptors), causing reduced internalization of M2/M4 upon agonist treatment, leading to reduced hippocampal acetylcholine release that is correctable by M2/M4 antagonist methoctramine or pertussis toxin.\",\n      \"method\": \"Dominant-negative GRK5 overexpression in cholinergic cells, GRK5 KO hippocampal slices, ACh release measurement, receptor immunoreactivity assay, pharmacological rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in cell line and KO slices with defined pharmacological rescue; single lab, two orthogonal model systems\",\n      \"pmids\": [\"19478075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GRK5 and GRK2 differentially phosphorylate neurotensin receptor 1 (NTSR1): GRK2 phosphorylates only C-terminal Ser residues in an agonist-dependent manner, while GRK5 phosphorylates Ser/Thr in intracellular loop 3 and C-terminus in an activation-independent manner; negatively charged lipids in the immediate vicinity of NTSR1 directly affect phosphorylation by GRKs.\",\n      \"method\": \"Nanodisc reconstitution in vitro phosphorylation, mass spectrometry phosphosite mapping, NTSR1 mutant panel\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with nanodisc technology plus MS site mapping and mutagenesis; single lab, rigorous biochemical approach\",\n      \"pmids\": [\"26120872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of full-length human GRK5 at 1.8 Å resolution reveals that the C-terminal tail (AST segment) forms novel interactions with the nucleotide and N-lobe not previously observed in other GRKs; the NLT is displaced from positions seen in other GRKs; autophosphorylation sites in the NLT can undergo rapid cis-autophosphorylation despite being >20 Å from the catalytic cleft.\",\n      \"method\": \"X-ray crystallography (1.8 Å), ATP-analog/sangivamycin co-crystals, structural comparison with AGC family members\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution crystal structure with functional structural analysis; single study but Tier 1 method\",\n      \"pmids\": [\"26032409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GRK5 forms a dynamic complex with agonist-occupied β2AR involving large conformational changes at the RH/catalytic domain interface; contacts occur between β2AR intracellular loops 2 and 3 and C-terminus with GRK5 RH bundle subdomain, membrane-binding surface, and kinase catalytic cleft, respectively.\",\n      \"method\": \"Cross-linking mass spectrometry, hydrogen-deuterium exchange MS, electron microscopy, mutagenesis, molecular dynamics simulations, computational docking\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — comprehensive integrated structural/biochemical approach with multiple orthogonal methods (HDX-MS, XL-MS, EM, mutagenesis, MD) in one rigorous study\",\n      \"pmids\": [\"28431242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The RGS domain of GRK5 contains a hydrophobic dimeric interface (HDI) region that mediates GRK5 self-association/dimerization and is critical for plasma membrane localization; disruption of dimerization (M165E/F166E) reduces PM localization and impairs PAR1-induced calcium release regulation, which is rescued by forced dimerization or by adding an extra membrane-binding region.\",\n      \"method\": \"GRK5/GRK4 chimeras, point mutagenesis, co-immunoprecipitation, acceptor photobleaching FRET, calcium release functional assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — coIP and FRET for dimerization, mutagenesis with functional readout; single lab, two orthogonal methods\",\n      \"pmids\": [\"24807909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ca2+·CaM binds primarily to the small lobe of the GRK5 kinase domain near elements critical for receptor interaction and membrane association, inhibiting receptor phosphorylation while activating the kinase for phosphorylation of soluble substrates; using the natural product malbrancheamide as a probe, the C-terminal lobe of CaM was shown to regulate membrane binding while the N-terminal lobe regulates receptor phosphorylation and kinase activation; in cells, malbrancheamide attenuates GRK5 nuclear translocation and blocks the hypertrophic response.\",\n      \"method\": \"Small-angle X-ray scattering, negative-stain EM, natural product chemical probe (malbrancheamide), in-cell nuclear translocation assay, hypertrophic gene expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — SAXS structural data plus chemical probe pharmacology and cell-based functional assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31337679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal/cryo structure of GRK5–calmodulin complex reveals that CaM N and C domains bind independently to two helical regions at GRK5 N and C termini: the C domain disrupts membrane association facilitating cytoplasmic translocation, while the N domain activates GRK5 via ordering of the amphipathic αN-helix and allosteric disruption of kinase-RH domain interaction, enabling phosphorylation of cytoplasmic substrates.\",\n      \"method\": \"Cryo-EM/crystal structure, molecular dynamics simulations, biochemical kinase assays, localization experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution structural data with computational and biochemical validation providing mechanistic model for CaM regulation of GRK5 localization and activity\",\n      \"pmids\": [\"33321095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK5 phosphorylates and inhibits the cardiac mineralocorticoid receptor (MR) upon β2-adrenergic receptor activation in cardiomyocytes, suppressing aldosterone-induced MR transcriptional activity; GRK5 deletion augments MR transcriptional activity and GRK5 is necessary for protective effects of eplerenone against aldosterone-induced apoptosis.\",\n      \"method\": \"CRISPR/Cas9 GRK5 deletion in H9c2 cells, GRK5 overexpression, co-immunoprecipitation, MR luciferase reporter, adult rat ventricular myocytes\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus reporter assay and CRISPR KO with functional readout; single lab, two orthogonal approaches\",\n      \"pmids\": [\"32326036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK5 is necessary to promote agonist-induced dissociation of SAP97 from β1AR; cardiac-specific deletion of GRK5 prevents adrenergic-induced dissociation of the β1AR-SAP97 complex and prevents increases in CaMKII activity in hearts.\",\n      \"method\": \"Cardiac-specific GRK5 conditional KO mice, co-immunoprecipitation of β1AR-SAP97 complex, CaMKII activity measurement after isoproterenol challenge\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with biochemical co-IP and kinase activity readout; single lab, two orthogonal methods\",\n      \"pmids\": [\"32507058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nuclear translocation of GRK5 is involved in cardiac fibroblast activation; fibroblast-specific GRK5 deletion inhibits angiotensin II-mediated fibroblast activation in vitro and reduces cardiac fibrosis and hypertrophy after chronic AngII infusion or ischemic injury in vivo.\",\n      \"method\": \"Adult cardiac fibroblast GRK5 KO, fibroblast-specific conditional KO mice, AngII infusion model, MI model, nuclear translocation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-specific KO with multiple in vivo disease models and mechanistic nuclear translocation assay; single lab, multiple orthogonal experiments\",\n      \"pmids\": [\"33500351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A peptide encoding the GRK5 N-terminal (GRK5nt) CaM-binding domain acts as a competitive inhibitor by binding Ca2+-CaM and preventing its association with endogenous GRK5, thereby blocking GRK5 nuclear accumulation after pressure overload and attenuating pathological NFAT and NF-κB transcription and cardiac hypertrophy.\",\n      \"method\": \"Adenoviral GRK5nt expression in NRVMs, transgenic cardiomyocyte-specific TgGRK5nt mice, TAC model, CaM-binding co-immunoprecipitation, NFAT/NF-κB reporters\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic peptide inhibitor with defined target (CaM-GRK5 interaction), cell and in vivo confirmation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33785612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Heterotrimeric Gq acts as a determinant of GRK subtype selectivity: upon Ang II stimulation of AT1R, β-arrestin recruitment depends on both GRK2/3 and GRK5/6; with β-arrestin-biased ligand TRV027 or pharmacological/genetic loss of Gq, GRK selectivity shifts to solely GRK5/6. Single-molecule imaging shows that under Gq-inactive conditions, AT1R and GRK5 (but not GRK2) relocate to an immobile phase.\",\n      \"method\": \"GRK-selective pharmacological inhibition, GRK genetic knockout, β-arrestin recruitment assay (BRET/NanoBiT), single-molecule live-cell imaging\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pharmacological and genetic perturbations with single-molecule imaging readout; multiple orthogonal methods, rigorous controls\",\n      \"pmids\": [\"35078997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Catalytic inactivation of GRK5 (K215R knock-in mice) causes marked decline in cardiac function with increased apoptosis and fibrosis at baseline; nuclear restriction of K215R GRK5 in cardiomyocytes enhances cell death with higher p53 levels; K215R mutation promotes fibroblast-to-myofibroblast transition.\",\n      \"method\": \"Knock-in mouse model (K215R catalytic-dead GRK5), echocardiography, histology, in vitro cardiomyocyte and fibroblast studies\",\n      \"journal\": \"JACC. Basic to translational science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic-dead knock-in mouse with cell biological mechanistic follow-up; single lab, two experimental systems\",\n      \"pmids\": [\"35540100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GRK5 is essential for finerenone-induced GRK5-dependent MR phosphorylation and inverse agonism in cardiomyocytes; GRK5 genetic deletion renders finerenone incapable of blocking cardiac MR transcriptional activity, establishing GRK5 as a co-repressor of the cardiac mineralocorticoid receptor.\",\n      \"method\": \"GRK5 genetic deletion (H9c2 cells), MR luciferase reporter assay, MR phosphorylation assay, finerenone vs. eplerenone comparison\",\n      \"journal\": \"World journal of cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic deletion with reporter and phosphorylation assay; single lab, single study but two pharmacological comparators\",\n      \"pmids\": [\"35582468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GRK5 regulates phosphorylation of HDAC5 in pancreatic β cells; β cell-specific Grk5 KO mice show impaired glucose tolerance with reduced β cell mass and upregulation of cell cycle inhibitor Cdkn1a, with reduced transcription of immediate-early genes (Nr4a1, Fosb, Junb, Arc, Egr1, Srf) downstream of HDAC5 phosphorylation.\",\n      \"method\": \"β cell-specific Grk5 KO mice, glucose tolerance test, β cell mass quantification, RNA sequencing, HDAC5 phosphorylation assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-specific KO with defined pathway (GRK5-HDAC5-IEG) and multiple molecular readouts; single lab\",\n      \"pmids\": [\"37520700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GRK5 phosphorylates HDAC6 in chondrocytes, promoting HDAC6 phosphorylation; KLF9 transcriptionally drives GRK5 expression by directly targeting the GRK5 promoter; GRK5 knockdown eliminates KLF9 overexpression effects on chondrocyte ECM degradation and apoptosis in osteoarthritis.\",\n      \"method\": \"ChIP/luciferase for KLF9-GRK5 promoter binding, GRK5-HDAC6 co-immunoprecipitation, HDAC6 phosphorylation assay, siRNA knockdown, HDAC6 inhibitor rescue\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing upstream regulation plus biochemical co-IP and phosphorylation with functional rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39779910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GRK5 phosphorylates HDAC5 and regulates the HDAC5/Smad3 pathway in renal fibrosis; nuclear-translocated GRK5 upregulates HDAC5, which prevents MEF2A transcriptional activity and represses Smad7, leading to Smad3 activation. GRK5 inhibition attenuates renal fibrosis.\",\n      \"method\": \"GRK5 overexpression/knockdown in renal cells, nuclear fractionation, HDAC5 and Smad3 pathway Western blot, MEF2A reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pathway analysis with defined molecular intermediates; single lab, single study\",\n      \"pmids\": [\"38206179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GRK5 inhibition rescues p.Phe508del-CFTR plasma membrane traffic and function in human airway cells; GRK5 siRNA knockdown validated in a genome-wide siRNA screen of >9,000 genes as a regulator of p.Phe508del-CFTR plasma membrane rescue.\",\n      \"method\": \"Genome-wide siRNA high-content microscopy screen, siRNA validation, functional CFTR assay in primary and immortalized airway cells\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — validated siRNA screen with functional CFTR readout; mechanistic link to CFTR trafficking is established but pathway not fully defined; single study\",\n      \"pmids\": [\"40040803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GRK5 is required for FPR2 endocytosis: GRK5 phosphorylates FPR2 C-terminal sites enabling β-arrestin recruitment; however, β-arrestin recruitment per se is not essential for FPR2 endocytosis—rather, β-arrestin determines postendocytic delivery to subcellular compartments and the magnitude of downstream ERK signaling.\",\n      \"method\": \"GRK5-selective pharmacological/genetic manipulation, β-arrestin KO cells, β-arrestin recruitment BRET assay, internalization assay, subcellular trafficking imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological dissection of GRK5 vs. β-arrestin roles with multiple readouts; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"39706266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PHLPP2 physically interacts with endogenous GRK5 in neonatal rat ventricular myocytes; PHLPP2 knockdown enhances PE-induced nuclear accumulation of GRK5 and potentiates hypertrophic growth, while PHLPP2 overexpression (requiring phosphatase activity) blocks PE-induced GRK5 nuclear accumulation and hypertrophy in a GRK5-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of PHLPP2, adenoviral overexpression, nuclear fractionation, cell size measurement, fetal gene expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP interaction confirmed plus reciprocal gain/loss-of-function with defined functional readout; single lab, two orthogonal methods\",\n      \"pmids\": [\"29628444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GRK5 regulates PAR1 desensitization in platelets: GG homozygotes for rs10886430 have ~90% lower GRK5 protein in platelets, leading to reduced PAR1 internalization, elevated platelet responsiveness to thrombin and PAR1 agonist (but not PAR4 agonist), and enhanced thrombus formation in vitro and in vivo. These findings were corroborated in GRK5-/- iPSC-derived megakaryocytes, Grk5-deficient murine platelets, and with GRK5 inhibitor treatment.\",\n      \"method\": \"Human platelet GRK5 protein quantification in GG vs AA donors, PAR1 internalization assay, platelet activation functional assay, microfluidic endothelialized system, GRK5 KO iPSC-megakaryocytes, Grk5-deficient mouse platelets, murine arterial thrombosis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal model systems (human platelets, iPSC-MK, mouse KO, pharmacological inhibition, in vivo thrombosis) all converging on PAR1 desensitization mechanism\",\n      \"pmids\": [\"41557909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GRK5 forms a protein complex with the GABA(B2) subunit of GABA(B) receptors at the plasma membrane (demonstrated by FRET between GRK5 and GB2R-Venus, confirmed by co-immunoprecipitation), mediating desensitization of GABA(B) receptor-operated K+ currents upon repeated baclofen application.\",\n      \"method\": \"FRET (cerulean/Venus fluorophores), co-immunoprecipitation, Xenopus oocyte electrophysiology, BHK cell coexpression\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET and co-IP with functional desensitization readout; single lab, two orthogonal methods\",\n      \"pmids\": [\"17013811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB1 receptor signaling in smooth muscle proceeds via GRK5 phosphorylation (not Gβγ): kinase-deficient GRK5(K215R) abolishes CB1 receptor internalization and ERK1/2/Src kinase activation; β-arrestin1/2 siRNA abolishes ERK1/2 activity; GRK5/β-arrestin-activated ERK1/2 phosphorylates RGS4 at Ser103/Ser108 to accelerate Gαq inactivation and inhibit muscle contraction.\",\n      \"method\": \"Kinase-deficient GRK5 K215R expression, β-arrestin siRNA, CB1 receptor internalization assay, ERK1/2 activity assay, RGS4 phosphorylation assay, RGS4 mutant (S103A/S108A), contraction assay\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — kinase-dead mutant, siRNA epistasis, substrate site mutagenesis, and functional contraction readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24407588\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GRK5 is a serine/threonine kinase that constitutively associates with the plasma membrane via a C-terminal amphipathic helix and phosphorylates agonist-occupied GPCRs (including β2AR, rhodopsin, muscarinic, neurotensin, FPR2, and CB1 receptors) to initiate desensitization; its activity is activated by phospholipid-stimulated autophosphorylation at Ser484/Thr485 and inhibited by PKC phosphorylation of C-terminal sites, actin binding (at the N-terminus), and by Ca2+/calmodulin, which binds both N- and C-terminal helices to simultaneously inhibit receptor phosphorylation and disrupt membrane association, thereby triggering GRK5 nuclear translocation where it acts in a kinase-independent manner as a direct DNA-binding co-activator of NFAT and NF-κB to drive pathological cardiac hypertrophic gene transcription, and also phosphorylates non-GPCR substrates including HDAC5, moesin (Thr66), the mineralocorticoid receptor, β-arrestin1 (Ser412), and PAR1, integrating canonical receptor desensitization with non-canonical nuclear signaling in the heart, vasculature, neurons, and other tissues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GRK5 is a membrane-associated serine/threonine kinase that phosphorylates agonist-occupied G protein-coupled receptors to initiate desensitization, and it doubles as a calcium-gated nuclear transcriptional regulator [#1, #13]. Unlike β-adrenergic receptor kinase, GRK5 phosphorylates rhodopsin in a light-dependent manner, is not activated by Gβγ, lacks an isoprenylation site, and instead remains constitutively associated with the plasma membrane [#0, #1, #6]. Membrane targeting and full catalytic competence depend on a C-terminal amphipathic helix and on phospholipid-stimulated autophosphorylation at Ser484/Thr485, while a hydrophobic dimerization interface in the RGS homology domain further supports plasma membrane localization [#2, #5, #19]. GRK5 phosphorylates a broad panel of receptors—β2AR, m2 muscarinic, rhodopsin, neurotensin receptor 1, FPR2, CB1, and PAR1—forming a dynamic complex with agonist-occupied β2AR, and its receptor engagement controls desensitization, internalization, and the balance of β-arrestin-dependent signaling [#1, #16, #18, #33, #37, #35]. Its activity is negatively tuned by PKC phosphorylation of the C-terminus and by N-terminal actin binding, and is gated by Ca2+/calmodulin, which binds independent helical regions at the N- and C-termini to simultaneously block receptor phosphorylation, disrupt membrane association, and drive nuclear translocation while activating phosphorylation of soluble substrates [#3, #4, #20, #21]. In the nucleus GRK5 binds DNA directly via an NLS-containing region and acts in a kinase-independent manner as a co-activator of NFAT and NF-κB to drive pathological cardiac hypertrophic gene transcription and cardiac fibroblast activation [#11, #13, #12, #24]. Beyond GPCRs, GRK5 phosphorylates moesin, the cardiac mineralocorticoid receptor, β-arrestin1, HDAC5, and HDAC6, linking it to cancer cell migration, mineralocorticoid receptor repression, and fibrotic and metabolic programs [#14, #22, #8, #29, #31, #30]. A common GRK5 Q41L polymorphism enhances β-adrenergic desensitization and protects against catecholamine-induced cardiomyopathy [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established GRK5 as a distinct GRK family member by showing it phosphorylates rhodopsin light-dependently without Gβγ activation or isoprenylation, distinguishing its membrane-targeting mechanism from βARK.\",\n      \"evidence\": \"Baculovirus/Sf9 overexpression with in vitro kinase assay and sequence analysis\",\n      \"pmids\": [\"7685906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane-association mechanism not yet defined\", \"Physiological GPCR substrates beyond rhodopsin not addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined GRK5 as a broad receptor kinase acting on β2AR, m2 muscarinic, and rhodopsin, mapped autophosphorylation to Ser484/Thr485, and showed constitutive membrane association rather than agonist-triggered translocation.\",\n      \"evidence\": \"Sf9 purification, in vitro kinase and autophosphorylation site mapping\",\n      \"pmids\": [\"8120045\", \"8288567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of autophosphorylation not yet established\", \"Membrane-targeting motif unidentified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed phospholipid-stimulated autophosphorylation at Ser484/Thr485 activates the kinase, linking lipid sensing to catalytic competence.\",\n      \"evidence\": \"In vitro kinase assay with S484A/T485A mutant and phospholipid binding\",\n      \"pmids\": [\"8144599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of autophosphorylation across the catalytic cleft unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified PKC phosphorylation of the C-terminus as a negative regulatory input that lowers receptor phosphorylation and membrane binding without affecting phospholipid binding.\",\n      \"evidence\": \"In vitro PKC phosphorylation, intact-cell PMA treatment, kinetic and membrane-binding analysis\",\n      \"pmids\": [\"9013639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of PKC crosstalk not established\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Revealed N-terminal actin binding as an inhibitory mechanism and calmodulin as a switch that displaces GRK5 from actin to permit soluble-substrate phosphorylation.\",\n      \"evidence\": \"In vitro binding/kinase assays with N-terminal mutagenesis and measured Kd values\",\n      \"pmids\": [\"9685424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of actin/CaM switching not yet tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"First implicated nuclear GRK5 in disease by showing it accumulates in the nucleus of hypertensive heart-failure-prone cardiomyocytes, hinting at a non-receptor role.\",\n      \"evidence\": \"Subcellular fractionation and confocal co-localization in SHHF vs WKY myocytes\",\n      \"pmids\": [\"12052842\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of nuclear localization tested\", \"Single rat model, no causal manipulation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified a C-terminal amphipathic helix (aa 546–565) as the determinant of plasma membrane localization and lipid-dependent activity.\",\n      \"evidence\": \"GFP-fusion live-cell imaging with hydrophobic-residue mutagenesis and autophosphorylation assay\",\n      \"pmids\": [\"14976207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other regions contribute to membrane binding not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established GRK5 as constitutively pre-associated with β2AR at the membrane and extended its desensitization role to GABA(B) receptors.\",\n      \"evidence\": \"BRET2/FRET co-localization, cell-free membrane phosphorylation, GRK immunodepletion, oocyte electrophysiology\",\n      \"pmids\": [\"18034461\", \"17013811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pre-coupling stoichiometry and dynamics not quantified\", \"GABA(B) interaction not structurally defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked a GRK5 coding polymorphism (Q41L) to enhanced β-adrenergic desensitization and cardioprotection, demonstrating physiological consequence of GRK5 activity variation.\",\n      \"evidence\": \"Transfected cell functional assays, transgenic mice, catecholamine challenge\",\n      \"pmids\": [\"18425130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of the L41 gain-of-function not fully defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Expanded GRK5 substrate scope beyond receptors to β-arrestin1 (Ser412) and to selective regulation of presynaptic M2/M4 autoreceptor desensitization in neurons.\",\n      \"evidence\": \"Co-IP, phosphorylation/mutagenesis with ERK readout; GRK5 KO hippocampal slices with pharmacological rescue\",\n      \"pmids\": [\"19661922\", \"19478075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of β-arrestin1 phosphorylation across receptors unknown\", \"Behavioral consequences of cholinergic deficit not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a kinase-independent cytoskeletal/membrane-remodeling function: GRK5 bundles F-actin and shapes neuronal dendrites and spines, with KO mice showing learning/memory deficits.\",\n      \"evidence\": \"Domain mutagenesis, in vitro actin bundling, live imaging, GRK5 KO mouse behavior/morphology\",\n      \"pmids\": [\"21930777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between actin function and nuclear/receptor functions unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established the mechanistic basis of nuclear GRK5 action: an NLS/CaM-dependent DNA-binding region plus an NES enabling Ca2+/CaM-regulated nucleocytoplasmic shuttling, and direct upregulation of NF-κB transcription in cardiomyocytes.\",\n      \"evidence\": \"Chimera/mutagenesis, in vitro DNA binding, localization imaging; adenoviral/siRNA NF-κB reporter, EMSA, NLS mutant\",\n      \"pmids\": [\"23658733\", \"24174526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DNA sequence specificity of GRK5 binding not defined\", \"Direct NF-κB target genes not enumerated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated nuclear GRK5 drives NFAT-dependent hypertrophic transcription via direct DNA binding without phosphorylation, with epistasis through NFATc3 establishing it as a transcriptional co-activator in heart disease.\",\n      \"evidence\": \"NFAT-luciferase, transgenic/KO mouse TAC, adenoviral transfer, NFATc3 KO epistasis\",\n      \"pmids\": [\"25332207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GRK5 contacts NFAT directly or via shared DNA elements not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended GRK5 kinase substrates to moesin (Thr66), linking it to cytoskeletal/focal-adhesion regulation and prostate cancer cell motility.\",\n      \"evidence\": \"MS phosphoproteomics, in vitro kinase, T66 mutagenesis, siRNA, xenograft\",\n      \"pmids\": [\"24755472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signal triggering moesin phosphorylation not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed RGS-domain dimerization (HDI region) supports membrane localization and PAR1-coupled calcium regulation, adding self-association to GRK5's membrane-targeting repertoire.\",\n      \"evidence\": \"Chimeras, point mutagenesis (M165E/F166E), co-IP, FRET, calcium release assay\",\n      \"pmids\": [\"24807909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological prevalence and regulation of dimerization unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a GRK5-dependent, kinase-required CB1 receptor signaling route through β-arrestin to ERK and RGS4 phosphorylation controlling smooth muscle contraction.\",\n      \"evidence\": \"GRK5 K215R, β-arrestin siRNA epistasis, RGS4 site mutagenesis, contraction assay\",\n      \"pmids\": [\"24407588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue generality of the CB1-GRK5-RGS4 axis untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided structural and biochemical mechanisms: a 1.8 Å full-length structure explaining cis-autophosphorylation, and nanodisc reconstitution showing GRK5 phosphorylates NTSR1 activation-independently with lipid-dependent regiospecificity distinct from GRK2.\",\n      \"evidence\": \"X-ray crystallography; nanodisc in vitro phosphorylation with MS site mapping and NTSR1 mutants\",\n      \"pmids\": [\"26032409\", \"26120872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational changes during receptor engagement not captured by static structure\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the dynamic GRK5–β2AR engagement, mapping receptor contacts to the RH bundle, membrane-binding surface, and catalytic cleft and revealing large interdomain rearrangements.\",\n      \"evidence\": \"XL-MS, HDX-MS, EM, mutagenesis, MD simulations, docking\",\n      \"pmids\": [\"28431242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution receptor-bound structure still lacking\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Clarified how Ca2+·CaM allosterically inhibits receptor phosphorylation while activating soluble-substrate phosphorylation, and showed a chemical probe (malbrancheamide) can block GRK5 nuclear translocation and hypertrophy.\",\n      \"evidence\": \"SAXS, negative-stain EM, natural-product probe, in-cell translocation and hypertrophy assays\",\n      \"pmids\": [\"31337679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity and in vivo efficacy of the probe not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the CaM-GRK5 structure showing independent N- and C-domain engagement that separates membrane disruption (translocation) from kinase activation, unifying the calcium-gated localization switch.\",\n      \"evidence\": \"Cryo-EM/crystal structure, MD, kinase assays, localization experiments\",\n      \"pmids\": [\"33321095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell kinetics of the CaM-driven switch under physiological calcium not measured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended GRK5 cardiac substrates and partners to the mineralocorticoid receptor (repression upon β2AR activation) and the β1AR-SAP97-CaMKII complex, broadening its cardiomyocyte signaling roles.\",\n      \"evidence\": \"CRISPR KO/overexpression, co-IP, MR reporter; cardiac-specific conditional KO with co-IP and CaMKII activity\",\n      \"pmids\": [\"32326036\", \"32507058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MR phosphosites not mapped\", \"Direct vs indirect effects on the β1AR-SAP97 complex unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated nuclear GRK5 drives cardiac fibroblast activation and that a CaM-binding peptide inhibitor (GRK5nt) blocks nuclear accumulation and pathological NFAT/NF-κB transcription, providing a therapeutic proof-of-concept.\",\n      \"evidence\": \"Fibroblast-specific KO with AngII/MI models; GRK5nt adenoviral/transgenic mice, TAC, CaM co-IP, reporters\",\n      \"pmids\": [\"33500351\", \"33785612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fibroblast nuclear GRK5 transcriptional targets not enumerated\", \"GRK5nt pharmacokinetics/specificity untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Refined receptor-level selectivity (Gq determines GRK2/3 vs GRK5/6 usage at AT1R) and revealed that catalytic activity is required for cardiac homeostasis, since catalytic-dead K215R mice develop dysfunction and fibrosis.\",\n      \"evidence\": \"GRK inhibition/KO with β-arrestin recruitment and single-molecule imaging; K215R knock-in mice with echocardiography/histology\",\n      \"pmids\": [\"35078997\", \"35540100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nuclear-restricted catalytic-dead GRK5 raises p53 mechanistically unclear\", \"Generality of Gq-gated selectivity across receptors limited\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Broadened GRK5's substrate/regulatory network to HDAC family kinases—HDAC6 in chondrocytes (downstream of KLF9) and HDAC5/Smad3 in renal fibrosis—and to FPR2 endocytic control, linking GRK5 to osteoarthritis, renal fibrosis, and trafficking.\",\n      \"evidence\": \"ChIP/luciferase, co-IP, phosphorylation and rescue assays (HDAC6); overexpression/knockdown with pathway Western and MEF2A reporter (HDAC5); GRK5/β-arrestin genetic dissection of FPR2 trafficking\",\n      \"pmids\": [\"39779910\", \"38206179\", \"39706266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HDAC phosphosites not all mapped\", \"Whether these are kinase-dependent or nuclear scaffolding roles partly unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected GRK5 to CFTR rescue and refined its β-cell metabolic role, identifying GRK5 as a regulator of p.Phe508del-CFTR plasma membrane trafficking and of HDAC5/immediate-early-gene programs supporting β-cell mass.\",\n      \"evidence\": \"Genome-wide siRNA screen with CFTR functional validation; β-cell-specific Grk5 KO with GTT, β-cell mass, RNA-seq, HDAC5 phosphorylation\",\n      \"pmids\": [\"40040803\", \"37520700\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GRK5-CFTR mechanistic pathway undefined\", \"Direct β-cell GRK5 substrate driving IEG program not pinned down\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established a clinically relevant GRK5 role in hemostasis: low platelet GRK5 (via rs10886430) impairs PAR1 desensitization, increasing thrombin responsiveness and thrombus formation.\",\n      \"evidence\": \"Human platelet quantification, PAR1 internalization/activation assays, microfluidics, GRK5 KO iPSC-megakaryocytes, Grk5-deficient mouse platelets, in vivo thrombosis\",\n      \"pmids\": [\"41557909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PAR1 phosphosites targeted by GRK5 in platelets not mapped\", \"Selectivity over PAR4 mechanism not fully explained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the membrane-receptor kinase, cytoskeletal, and nuclear DNA-binding/transcriptional functions of GRK5 are coordinately partitioned in a given cell, and the DNA sequence specificity of nuclear GRK5, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genome-wide map of nuclear GRK5 DNA occupancy\", \"Quantitative rules governing receptor- vs nuclear-pool allocation unknown\", \"Direct vs cofactor-mediated transcriptional contacts for NFAT/NF-κB undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 8, 14, 16, 33, 37]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [13, 14]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [13, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 5, 9]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 5, 6, 19]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 11, 13, 24]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 18, 26, 33, 37]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 13, 24, 35]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ADRB2\", \"ARRB1\", \"CALM1\", \"ACTB\", \"NR3C2\", \"PHLPP2\", \"SAP97\", \"HDAC5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}